Jane Wasman's most recent trade in SELLAS Life Sciences Group Inc was a trade of 20,000 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on May 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group... | Jane Wasman | Director | Purchase of securities on an exchange or from another person at price $ 1.69 per share. | 30 May 2025 | 20,000 | 30,400 (0%) | 0% | 1.7 | 33,800 | Common Stock |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 3,000 | 3,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 2,500 | 12,500 (0%) | 0% | 0 | Common Stock | |
| SELLAS Life Sciences Group... | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 12,500 | 22,900 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 25,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| SELLAS Life Sciences Group... | Wasman Jane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 6,000 | 10,400 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 25,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
| SELLAS Life Sciences Group... | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 9,500 | 9,500 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 2,500 | 4,400 (0%) | 0% | 0 | Common Stock | |
| Athersys Inc | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 22,321 | 35,141 (0%) | 0% | 0 | Common Stock | |
| Athersys Inc | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 32,042 | 64,084 | - | - | Stock Option (right to purchase) | |
| Athersys Inc | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,820 | 12,820 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 25,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| SELLAS Life Sciences Group... | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 7,125 | 7,125 | - | - | Stock Option (Right to Buy) | |
| SELLAS Life Sciences Group... | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 1,900 | 1,900 (0%) | 0% | 0 | Common Stock | |
| Athersys Inc | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 50,000 | 50,000 | - | - | NonQualified Stock Option (right to purchase) | |
| Athersys Inc | Jane Wasman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2020 | 100,000 | 100,000 | - | - | NonQualified Stock Option (right to purchase) |